| NCT05958121 | IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2023-08-09 | 2027-09 | 2027-09 |
| NCT05359445 | IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor | RECRUITING | PHASE1 | 2022-05-19 | 2029-12 | 2025-11 |
| NCT02149225 | GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients | COMPLETED | PHASE1 | 2014-10 | 2018-06 | 2018-06 |
| NCT01403285 | Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma | TERMINATED | PHASE1 | 2011-08 | 2014-04 | 2014-04 |
| NCT01265901 | IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma | COMPLETED | PHASE3 | 2010-12 | 2015-07 | 2015-07 |
| NCT00785122 | IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101) | COMPLETED | PHASE1, PHASE2 | 2008-06 | 2013-05 | 2011-01 |
| NCT00523159 | IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease | COMPLETED | PHASE2 | 2007-05 | 2009-08 | 2009-08 |